Market outlook of the global pulmonary hypertension market

Pulmonary hypertension is an example of a rare disease that affects arteries carrying blood to the lungs. The narrowing, or blockage of these arteries results in pulmonary hypertension. The recent increase in the sales of ERAs that gained global acceptance due to its oral mode of administration is expected to aid this market in surpassing USD 4 billion by 2019.

Technavio’s market research analyst has estimated the Americas to account for more than 52% of the total market share by 2019. This region’s high market share can be attributed to factors such as the increasing focus on combination therapies and the recent increase in the number of geriatric population in this region during the forecast period.

Competitive landscape and key vendors

This market is highly competitive and is dominated by the presence of large vendors like Actelion, Bayer, GlaxoSmithKline, and United Therapeutics.  The acceptance and launch of novel formulations is expected to propel the revenue generated by the vendors in this market.

Key leading vendors in this market are -

• Actelion
• Bayer
• GlaxoSmithKline
• United Therapeutics

Other prominent vendors analyzed in this market study are Aires Pharmaceuticals, Arena Pharmaceuticals, Bial, DEKA, Dong-A ST, Gilead, Merck, Northern Therapeutics, Novartis, Pfizer, PhaseBio, Radikal Therapeutics, Reata Pharmaceuticals, and SteadyMed.

Formulation-based segmentation of the pulmonary hypertension market

• Oral
• Injection
• Inhalation

In this market analysis, Technavio’s market research analysts have estimated the oral segment to account for more than 70% of the total market share by 2019. This segment dominates the market as many companies prefer developing oral formulations as it does not involve widespread animal, and human efficacy and safety studies.

Segmentation by mechanism of action and analysis of the pulmonary hypertension market

• Endothelin receptor antagonists (ERAs)
• Prostacyclin analogs
• Phosphodiesterase inhibitors (PDE)
• Soluble guanylate cyclase stimulators (sGC)

The ERA segment accounts for almost 60% of the total market share by 2019 and aids in reducing high blood pressure by suppressing the pulmonary constriction. As endothelin is a 21-amino acid peptide involved in pulmonary vasoconstriction,   drugs acting on them bind to ET-A and B receptors and reduce constriction.

Key questions answered in the report include

What will the market size and the growth rate be in 2019?

• What are the key factors driving the global pulmonary hypertension market?
• What are the key market trends impacting the growth of the global pulmonary hypertension market?
• What are the challenges to market growth?
• Who are the key vendors in the global pulmonary hypertension market?
• What are the market opportunities and threats faced by the vendors in the global pulmonary hypertension market?
• Trending factors influencing the market shares of APAC, EMEA, and the Americas?
• What are the key outcomes of the five forces analysis of the global pulmonary hypertension market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Hypertension Drugs Market 2014-2018
• Global Pulmonary Drug Delivery Systems Market 2015-2019
• Global Chronic Obstructive Pulmonary Disease (COPD) Market 2014-2018
• Global Pulmonary Drug Delivery Systems Market 2015-2019